Home / Stocks / FSPKF

Fisher & Paykel Healthcare Corporation Limited (FSPKF, Medical devices) Stock Valuation & Fair Value

Significantly overvalued

Fisher & Paykel Healthcare Corporation Limited (FSPKF, Medical devices) trades at a current P/E of 53.0, about 45% above its historical normal valuation, with a forward growth estimate of 16.0% and a PEG of 3.31. Analysts' one-year estimates have been hit 45% of the time. Priced at its historical normal P/E of 36.6 on the same blended earnings, the 2026-11-06 close of $26.99 corresponds to about $18.60 a share. This is a valuation reference, not a price target. The $26.99 close is the one the P/E is read at; the technical context below uses the 2026-11-05 close, $27.01.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-07
Current P/E
53.0
Normal P/E
36.6
PEG
3.31
Fwd growth
16.0%
Div yield
1.3%
RSI (14)
56.2
Neutral
Technical context
  • Price $27.01 at the Nov 5 close, 0.4% above the 20-day average ($26.91) and 2.5% above the 50-day ($26.36).
  • RSI (14) at 56.2.
  • 52-week range $19.01 to $28.09: the price is 3.8% below the high and 42.1% above the low.

Valuation flags

Verdict history

tickerseer's rating has not changed since 2026-09-19, but its reason has: it read poor on forward returns then and reads significantly overvalued now.

Current P/E and rating by weekCurrent P/E moved from 50.8 to 53.0 between 2026-09-18 and 2026-10-30, against a normal P/E of 36.6, with 0 rating changes over 7 recorded weeks.2026-09-18: P/E 50.8, Poor on forward returns, recalculated for the week of 2026-09-192026-09-18: P/E 50.8, Poor on forward returns, recorded live 2026-09-212026-09-25: P/E 50.7, Poor on forward returns, recalculated for the week of 2026-09-262026-09-25: P/E 50.7, Poor on forward returns, recorded live 2026-09-282026-10-02: P/E 51.3, Significantly overvalued, recalculated for the week of 2026-10-032026-10-02: P/E 51.3, Significantly overvalued, recorded live 2026-10-052026-10-09: P/E 51.5, Significantly overvalued, recalculated for the week of 2026-10-102026-10-09: P/E 51.5, Significantly overvalued, recorded live 2026-10-122026-10-16: P/E 51.4, Significantly overvalued, recalculated for the week of 2026-10-172026-10-16: P/E 51.4, Significantly overvalued, recorded live 2026-10-192026-10-23: P/E 55.2, Significantly overvalued, recalculated for the week of 2026-10-242026-10-23: P/E 55.2, Significantly overvalued, recorded live 2026-10-262026-10-30: P/E 53.0, Significantly overvalued, recalculated for the week of 2026-10-312026-10-30: P/E 53.0, Significantly overvalued, recorded live 2026-11-0240.045.050.055.0Sep 18Sep 28Oct 9Oct 20Oct 30Normal P/E 36.6
Poor on forward returnsSignificantly overvalued

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 50.8+39%Poor on forward returns (recalculated)
2026-09-26P/E 50.7+38%Poor on forward returns (recalculated)
2026-10-24P/E 55.2+51%Significantly overvalued (recalculated)
2026-11-02P/E 53.0+45%Significantly overvalued ← now
Show all 14 readings
WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 50.8+39%Poor on forward returns (recalculated)
2026-09-21P/E 50.8+39%Poor on forward returns
2026-09-26P/E 50.7+38%Poor on forward returns (recalculated)
2026-09-28P/E 50.7+38%Poor on forward returns
2026-10-03P/E 51.3+40%Significantly overvalued (recalculated)
2026-10-05P/E 51.3+40%Significantly overvalued
2026-10-10P/E 51.5+41%Significantly overvalued (recalculated)
2026-10-12P/E 51.5+41%Significantly overvalued
2026-10-17P/E 51.4+40%Significantly overvalued (recalculated)
2026-10-19P/E 51.4+40%Significantly overvalued
2026-10-24P/E 55.2+51%Significantly overvalued (recalculated)
2026-10-26P/E 55.2+51%Significantly overvalued
2026-10-31P/E 53.0+45%Significantly overvalued (recalculated)
2026-11-02P/E 53.0+45%Significantly overvalued ← now

Frequently asked questions

Is Fisher & Paykel Healthcare Corporation Limited stock overvalued?

At a current P/E of 53.0 versus its historical normal P/E of 36.6, Fisher & Paykel Healthcare Corporation Limited trades about 45% above its typical valuation, with a PEG of 3.31 on 16.0% forward growth. tickerseer currently rates it significantly overvalued.

What is Fisher & Paykel Healthcare Corporation Limited's fair value and PEG?

Fisher & Paykel Healthcare Corporation Limited trades at a current P/E of 53.0 against a historical normal P/E of 36.6, a PEG of 3.31, and a forward growth estimate of 16.0%. Priced at its historical normal P/E of 36.6 on the same blended earnings, the 2026-11-06 close of $26.99 corresponds to about $18.60 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Fisher & Paykel Healthcare Corporation Limited changed?

tickerseer's rating has not changed since 2026-09-19, but its reason has: it read poor on forward returns then and reads significantly overvalued now.

Industry: Medical devices. Create a free account to see the full analysis: the SeerAI score, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track FSPKF free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.